Title : ( Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers as Potential Therapeutic Options for Pancreatic Cancer )
Authors: Fereshteh Asgharzadeh , Kiarash Roustai Geraylow , Majid Khazaei , Mohammadreza Nassiri , Seyed Mahdi Hassanian , Gordon A Ferns , Amir Avan ,
دانلود فایل برای اعضای دانشگاهAccess to full-text not allowed by authors
Abstract
The renin–angiotensin system (RAS) has been reported to have a role in carcinogenesis, and therefore it may be of value as a potential therapeutic target in inhibiting tumor growth. It has been shown that inhibition of RAS via angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor (ARBs) inhibitors may have a protective effect against several malignancies. Here we provide an overview on the potential value of RAS pathway and targeting via ACE/ARB inhibitors in pancreatic cancer. Whilst the potential role of RAS as a target for the treatment of pancreatic cancer has been reported, the use of candesartan with gemcitabine failed to improve outcomes in pancreatic cancer. Another study of 1–3 years using ARB was found to reduce the risk of pancreatic cancer. In line with these trials, there have been others demonstrating that the ARBs in combination with gemcitabine might improve clinical outcomes in patients with advanced pancreatic cancer. Prospective trials are warranted to investigate this hypothesis.
Keywords
, pancreatic cancer, ACE inhibitors, ARB inhibitors, renin–angiotensin system
@article{paperid:1090272,
author = {Fereshteh Asgharzadeh and Kiarash Roustai Geraylow and Majid Khazaei and Nassiri, Mohammadreza and Seyed Mahdi Hassanian and Gordon A Ferns and Amir Avan},
title = {Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor
Blockers as Potential Therapeutic Options for Pancreatic Cancer},
journal = {Current Cancer Drug Targets},
year = {2022},
volume = {22},
number = {10},
month = {October},
issn = {1568-0096},
pages = {785--795},
numpages = {10},
keywords = {pancreatic cancer; ACE inhibitors; ARB inhibitors; renin–angiotensin system},
}
%0 Journal Article
%T Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor
Blockers as Potential Therapeutic Options for Pancreatic Cancer
%A Fereshteh Asgharzadeh
%A Kiarash Roustai Geraylow
%A Majid Khazaei
%A Nassiri, Mohammadreza
%A Seyed Mahdi Hassanian
%A Gordon A Ferns
%A Amir Avan
%J Current Cancer Drug Targets
%@ 1568-0096
%D 2022
